Loading…
S. 1096119th CongressOn the floor calendarLatest action Apr 10, 2025Decoded by AI · checked against the record
Official title: Preserve Access to Affordable Generics and Biosimilars Act
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
S 1096 would make "pay-for-delay" drug patent settlements illegal, treating them as unfair competition enforced by the FTC.
45-second read · 5 questions answered below
This bill bans "pay-for-delay" deals in which brand-name drug companies pay generic or biosimilar makers to delay selling cheaper versions of a drug. Such deals would be presumed anti-competitive unless companies prove the payment was for a legitimate service or benefits competition overall. Normal settlements, like early market entry or covering legal costs, remain allowed.
The bill directly affects pharmaceutical and biotech companies involved in patent litigation and settlements. It also affects the FTC, which would enforce the new rule, and indirectly consumers, insurers, and government health programs.
By restricting these settlements, the bill could change how brand and generic companies resolve patent disputes and speed up generic drug availability. It also adds new reporting and certification requirements for tracking settlement agreements.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it's on the Senate floor calendar. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.